Allosteric Plus Catalytic BCR-ABL1 Inhibitors Promote Durable Responses

A selective allosteric ABL1 kinase inhibitor suppresses the growth of BCR-ABL1-driven CML.

Saved in:
Bibliographic Details
Published inCancer discovery Vol. 7; no. 5; p. 454
Format Journal Article
LanguageEnglish
Published United States 01.05.2017
Online AccessGet full text

Cover

More Information
Summary:A selective allosteric ABL1 kinase inhibitor suppresses the growth of BCR-ABL1-driven CML.
ISSN:2159-8274
2159-8290
DOI:10.1158/2159-8290.CD-RW2017-062